Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE DE JESUS GOMEZ CORTES

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1134177066
CMS profile
232321
Location
CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$32.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $32.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Actelion Pharmaceuticals US, Inc. $32.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE DE JESUS GOMEZ CORTES

NPI 1134177066 · CMS profile ID 232321

Allopathic & Osteopathic Physicians / Internal Medicine

CORAL GABLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134177066?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE DE JESUS GOMEZ CORTES, NPI 1134177066, CMS profile ID 232321. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134177066?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSE DE JESUS GOMEZ CORTES, NPI 1134177066, CMS profile ID 232321. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134177066?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSE DE JESUS GOMEZ CORTES, NPI 1134177066, CMS profile ID 232321, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134177066?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $32.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $32.0002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174198094 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $137.44 1
PY2020 $11.18 1
PY2025 $32.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $512,467.40 42
PY2024 Principal investigator $760,058.37 86
PY2023 Principal investigator $550,365.82 70
PY2022 Principal investigator $489,899.46 151
PY2021 Principal investigator $36,957.58 45
PY2020 Principal investigator $6,343.66 2
PY2019 Principal investigator $11,235.01 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $328.33 12/31/2024 Non-covered Recipient Entity
ELITE CLINICAL RESEARCH
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1155803528
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,542.25 12/19/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232432
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 12/19/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232534
Principal investigator 1 GlaxoSmithKline, LLC. $2,177.10 12/16/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTHCARE INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1156003077
Principal investigator 1 Chiesi USA, Inc. $14,553.50 12/13/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148225898
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 12/12/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232416
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 12/05/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232528
Principal investigator 1 SANOFI US SERVICES INC. $3,690.00 12/03/2024 Non-covered Recipient Entity
Interspond LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128721453
Principal investigator 1 SANOFI US SERVICES INC. $7,800.00 12/03/2024 Non-covered Recipient Entity
Interspond LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128721463
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,090.60 11/27/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232426
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $43,984.20 11/27/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232428
Principal investigator 1 Chiesi USA, Inc. $19,004.50 11/20/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148225204
Principal investigator 1 GlaxoSmithKline, LLC. $368.20 11/20/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTHCARE INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1156002679
Principal investigator 1 GlaxoSmithKline, LLC. $359.00 11/20/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTHCARE INC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1156003111
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 11/20/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232530
Principal investigator 1 Chiesi USA, Inc. $500.00 11/13/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224946
Principal investigator 1 GlaxoSmithKline, LLC. $9,990.00 11/06/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533828
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 10/31/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232526
Principal investigator 1 SANOFI US SERVICES INC. $8,461.00 10/21/2024 Non-covered Recipient Entity
Interspond LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128721429
Principal investigator 1 Chiesi USA, Inc. $36,327.50 10/18/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224212
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.20 10/14/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533982
Principal investigator 1 Chiesi USA, Inc. $500.00 10/04/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223756
Principal investigator 1 GlaxoSmithKline, LLC. $5,505.30 10/04/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533978
Principal investigator 1 SANOFI US SERVICES INC. $8,313.00 10/02/2024 Non-covered Recipient Entity
Interspond LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128721389
Principal investigator 1 GlaxoSmithKline, LLC. $8,518.00 09/25/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1127533832
Principal investigator 1 GlaxoSmithKline, LLC. $7,452.00 09/25/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533924
Principal investigator 1 GlaxoSmithKline, LLC. $5,460.00 09/20/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1127524820
Principal investigator 1 Chiesi USA, Inc. $500.00 09/18/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223078
Principal investigator 1 GlaxoSmithKline, LLC. $3,713.40 09/16/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533970
Principal investigator 1 SANOFI US SERVICES INC. $9,867.11 09/16/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721367
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,613.15 09/12/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232408
Principal investigator 1 Chiesi USA, Inc. $51,016.00 09/06/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148222684
Principal investigator 1 GlaxoSmithKline, LLC. $7,052.40 09/06/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127524822
Principal investigator 1 GlaxoSmithKline, LLC. $5,074.00 09/06/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1127524828
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,178.75 09/04/2024 Non-covered Recipient Entity
ELITE CLINICAL RESEARCH
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1110848561
Principal investigator 1 GlaxoSmithKline, LLC. $3,091.50 08/21/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533822
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35,582.95 08/15/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232404
Principal investigator 1 GlaxoSmithKline, LLC. $13,204.80 08/14/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533824
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 08/05/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721341
Principal investigator 1 SANOFI US SERVICES INC. $1,647.00 08/05/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721351
Principal investigator 1 Chiesi USA, Inc. $9,024.50 08/02/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148222034
Principal investigator 1 SANOFI US SERVICES INC. $11,205.98 07/29/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721337
Principal investigator 1 Chiesi USA, Inc. $30,472.00 07/24/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148221508
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,260.85 07/18/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232400
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 07/09/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232524
Principal investigator 1 GlaxoSmithKline, LLC. $9,094.50 07/08/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533922
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $7,500.00 06/26/2024 Non-covered Recipient Entity
INTERSPOND LLC
SEL-212/301 No dispute reported 06/30/2026 1146416997
Principal investigator 1 SANOFI US SERVICES INC. $21,775.00 06/24/2024 Non-covered Recipient Entity
Interspond LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128721275
Principal investigator 1 SWEDISH ORPHAN BIOVITRUM AB $709.09 06/24/2024 Non-covered Recipient Entity
INTERSPOND LLC
SEL-212/301 No dispute reported 06/30/2026 1146416999
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 06/20/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232540
Principal investigator 1 GlaxoSmithKline, LLC. $17,632.80 06/14/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533976
Principal investigator 1 Chiesi USA, Inc. $13,412.00 06/07/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148220400
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,012.50 06/06/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232396
Principal investigator 1 Chiesi USA, Inc. $1,775.00 05/24/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148220044
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 05/24/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232522
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 05/21/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232520
Principal investigator 1 GlaxoSmithKline, LLC. $3,276.00 05/17/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127524824
Principal investigator 1 Chiesi USA, Inc. $16,531.00 05/15/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148219874
Principal investigator 1 GlaxoSmithKline, LLC. $9,696.60 05/08/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533820
Principal investigator 1 SANOFI US SERVICES INC. $17,587.28 05/06/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721267
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $47,497.45 05/02/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232394
Principal investigator 1 GlaxoSmithKline, LLC. $9,273.60 04/15/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127524826
Principal investigator 1 GlaxoSmithKline, LLC. $4,186.80 04/15/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533826
Principal investigator 1 Chiesi USA, Inc. $10,942.00 04/10/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148218099
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 04/09/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232518
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 04/02/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232516
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 04/02/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232538
Principal investigator 1 SANOFI US SERVICES INC. $2,992.50 03/25/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721229
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 03/20/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232514
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 03/19/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232512
Principal investigator 1 GlaxoSmithKline, LLC. $7,462.80 03/18/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533818
Principal investigator 1 GlaxoSmithKline, LLC. $8,403.30 03/13/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533984
Principal investigator 1 Chiesi USA, Inc. $6,238.00 03/08/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148217033
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,577.35 03/07/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232386
Principal investigator 1 SANOFI US SERVICES INC. $7,065.42 03/04/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 02/29/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232510
Principal investigator 1 Chiesi USA, Inc. $2,118.00 02/21/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148216200
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 02/13/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232508
Principal investigator 1 GlaxoSmithKline, LLC. $5,497.20 02/09/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533972
Principal investigator 1 GlaxoSmithKline, LLC. $677.70 02/02/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533830
Principal investigator 1 SANOFI US SERVICES INC. $19,616.91 01/29/2024 Non-covered Recipient Entity
Interspond LLC
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128721165
Principal investigator 1 Chiesi USA, Inc. $15,530.00 01/19/2024 Non-covered Recipient Entity
INTERSPOND LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148214748
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,642.70 01/18/2024 Non-covered Recipient Entity
Praetorian Pharmaceutical Research, LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144232382
Principal investigator 1 GlaxoSmithKline, LLC. $5,175.90 01/17/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127533834
Principal investigator 1 GlaxoSmithKline, LLC. $4,149.00 01/12/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127533980
Principal investigator 1 GlaxoSmithKline, LLC. $2,285.10 01/03/2024 Non-covered Recipient Entity
Y & L ADVANCE HEALTH CARE
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1127533974